CRNX, Jefferies and Crinetics Pharmaceuticals
How Does Crinetics Pharmaceuticals Inc (CRNX) Stack Up Against Its Industry Peers?
Crinetics Pharmaceuticals Inc (CRNX) stock saw a decline, ending the day at $40.59 which represents a decrease of $-7.91 or -16.31% from the prior close of $48.5. The stock opened at $46.64 and touched a low of $40.
1don MSN
We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC ...
In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands against other biotech stocks with the biggest upside potential. While 2024 was a ...
J.P. Morgan analyst Jessica Fye has maintained their bullish stance on CRNX stock, giving a Buy rating yesterday.Stay Ahead of the ...
In trading on Monday, shares of Crinetics Pharmaceuticals Inc (Symbol: CRNX) crossed below their 200 day moving average of $50.81, changing hands as low as $50.52 per share. Crinetics ...
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases ...
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback